Curonix Receives the First Full-Body Peripheral Nerve Stimulator (PNS) FDA Clearance, including Craniofacial Pain Indication, for its Freedom® PNS System
09. Juli 2024 08:00 ET
|
Curonix LLC
Curonix Receives the First Full-Body Peripheral Nerve Stimulator (PNS) FDA Clearance, including Craniofacial Pain Indication, for its Freedom® PNS System.
SPR® Therapeutics Recognized as a Top Workplace in Northeast Ohio for the Third Year in a Row
23. Juni 2024 10:00 ET
|
SPR Therapeutics, Inc.
Medical Device Leader SPR Therapeutics again named a Top Workplace in Northeast Ohio
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
18. Januar 2024 08:00 ET
|
Curonix LLC
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
SPR Therapeutics Announces Completion of Enrollment in the RESET Clinical Trial of the SPRINT® PNS System for Low Back Pain
12. Dezember 2023 11:48 ET
|
SPR Therapeutics, Inc.
SPR Therapeutics Announces Completion of Enrollment in the RESET Clinical Trial of the SPRINT PNS System for Low Back Pain
Curonix Celebrates 1st Anniversary
01. November 2023 09:00 ET
|
Curonix LLC
POMPANO BEACH, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Today, Curonix LLC, a leading peripheral nerve stimulation company celebrated its first anniversary. In November 2022, Curonix completed the...
Independent clinical study shows Curonix’s Freedom® PNS System significantly reduces pain scores and medication usage
07. Juni 2023 07:00 ET
|
Curonix LLC
POMPANO BEACH, Fla., June 07, 2023 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to freeing patients from chronic pain, announced the publication of 24 months of data from...
Real-World Data from Over 6,100 Patients Corroborates Significant Pain Reduction from Prior Prospective Studies for Patients Treated with SPRINT® PNS
17. Mai 2023 10:16 ET
|
SPR Therapeutics, Inc.
CLEVELAND, May 17, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics announced the publication of a comprehensive real-world retrospective data analysis of over 6,100 patients demonstrating significant...
SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference
16. März 2023 08:00 ET
|
SPR Therapeutics, Inc.
CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients suffering from acute or...
SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System
03. Februar 2023 15:32 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Feb. 03, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic...
Real-World Retrospective Review of Axial Neck Pain Relief Following Peripheral Nerve Stimulation of Cervical Medial Branch Nerves
21. September 2022 15:02 ET
|
SPR Therapeutics, Inc.
- Data presented at Pacific Spine Pain Society annual meeting - CLEVELAND, Sept. 21, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics shared data on the use of peripheral nerve stimulation (PNS) to...